Cost of treating otitis media in Australia

P.S. Taylor, I. Faeth, M.K. Marks, C.B. Del Mar, S.A. Skull, M.L. Pezzullo, S.M. Havyatt, Harvey Coates

    Research output: Contribution to journalArticle

    25 Citations (Scopus)

    Abstract

    Objective: Otitis media (OM) is an inflammation of the middle ear. It is very common and associated with serious complications, including hearing loss. This study aimed to estimate the treatment costs of OM in Australia and the associated burden of disease (in disability-adjusted life-years). Methods: Little Australia-wide epidemiological information is available, so international studies in the main were used to estimate the incidence and prevalence by age and gender. These were triangulated against the available Australian data. Australian health data sets and data collected from the emergency department of a tertiary pediatric hospital were used to estimate the costs of primary care, pharmaceuticals, pathology and imaging, emergency department presentations, specialists, and admitted hospital care. Results: Excluding the costs of the complications and comorbidities associated with OM, treatment costs for the disease in 2008 were between AUS$100 and 400 million. Visits to general practitioners and medicines constituted a high proportion of these costs. Antibiotic prescribing rates remain high despite clear evidence for a limited benefit from antibiotics for most OM cases and concerns regarding bacterial resistance. Conclusion: Treatment costs of OM in Australia are high and can only be estimated within a broad range. Further research on the links between antibiotics for OM and antibiotic resistance, and on the cost–effectiveness of prevention or amelioration of OM would be useful.
    Original languageEnglish
    Pages (from-to)133-141
    JournalExpert review of pharmacoeconomics and outcomes research
    Volume9
    Issue number2
    DOIs
    Publication statusPublished - 2009

    Fingerprint

    Otitis Media
    Costs and Cost Analysis
    Health Care Costs
    Anti-Bacterial Agents
    Hospital Emergency Service
    Cost of Illness
    Pediatric Hospitals
    Quality-Adjusted Life Years
    Microbial Drug Resistance
    Hearing Loss
    Tertiary Care Centers
    General Practitioners
    Comorbidity
    Primary Health Care
    Pathology
    Incidence
    Health
    Research
    Pharmaceutical Preparations

    Cite this

    Taylor, P. S., Faeth, I., Marks, M. K., Del Mar, C. B., Skull, S. A., Pezzullo, M. L., ... Coates, H. (2009). Cost of treating otitis media in Australia. Expert review of pharmacoeconomics and outcomes research, 9(2), 133-141. https://doi.org/10.1586/erp.09.6
    Taylor, P.S. ; Faeth, I. ; Marks, M.K. ; Del Mar, C.B. ; Skull, S.A. ; Pezzullo, M.L. ; Havyatt, S.M. ; Coates, Harvey. / Cost of treating otitis media in Australia. In: Expert review of pharmacoeconomics and outcomes research. 2009 ; Vol. 9, No. 2. pp. 133-141.
    @article{7f3250f91223431199f1eb627bfd9565,
    title = "Cost of treating otitis media in Australia",
    abstract = "Objective: Otitis media (OM) is an inflammation of the middle ear. It is very common and associated with serious complications, including hearing loss. This study aimed to estimate the treatment costs of OM in Australia and the associated burden of disease (in disability-adjusted life-years). Methods: Little Australia-wide epidemiological information is available, so international studies in the main were used to estimate the incidence and prevalence by age and gender. These were triangulated against the available Australian data. Australian health data sets and data collected from the emergency department of a tertiary pediatric hospital were used to estimate the costs of primary care, pharmaceuticals, pathology and imaging, emergency department presentations, specialists, and admitted hospital care. Results: Excluding the costs of the complications and comorbidities associated with OM, treatment costs for the disease in 2008 were between AUS$100 and 400 million. Visits to general practitioners and medicines constituted a high proportion of these costs. Antibiotic prescribing rates remain high despite clear evidence for a limited benefit from antibiotics for most OM cases and concerns regarding bacterial resistance. Conclusion: Treatment costs of OM in Australia are high and can only be estimated within a broad range. Further research on the links between antibiotics for OM and antibiotic resistance, and on the cost–effectiveness of prevention or amelioration of OM would be useful.",
    author = "P.S. Taylor and I. Faeth and M.K. Marks and {Del Mar}, C.B. and S.A. Skull and M.L. Pezzullo and S.M. Havyatt and Harvey Coates",
    year = "2009",
    doi = "10.1586/erp.09.6",
    language = "English",
    volume = "9",
    pages = "133--141",
    journal = "Expert review of pharmacoeconomics and outcomes research",
    issn = "1473-7167",
    publisher = "Expert Reviews",
    number = "2",

    }

    Taylor, PS, Faeth, I, Marks, MK, Del Mar, CB, Skull, SA, Pezzullo, ML, Havyatt, SM & Coates, H 2009, 'Cost of treating otitis media in Australia' Expert review of pharmacoeconomics and outcomes research, vol. 9, no. 2, pp. 133-141. https://doi.org/10.1586/erp.09.6

    Cost of treating otitis media in Australia. / Taylor, P.S.; Faeth, I.; Marks, M.K.; Del Mar, C.B.; Skull, S.A.; Pezzullo, M.L.; Havyatt, S.M.; Coates, Harvey.

    In: Expert review of pharmacoeconomics and outcomes research, Vol. 9, No. 2, 2009, p. 133-141.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - Cost of treating otitis media in Australia

    AU - Taylor, P.S.

    AU - Faeth, I.

    AU - Marks, M.K.

    AU - Del Mar, C.B.

    AU - Skull, S.A.

    AU - Pezzullo, M.L.

    AU - Havyatt, S.M.

    AU - Coates, Harvey

    PY - 2009

    Y1 - 2009

    N2 - Objective: Otitis media (OM) is an inflammation of the middle ear. It is very common and associated with serious complications, including hearing loss. This study aimed to estimate the treatment costs of OM in Australia and the associated burden of disease (in disability-adjusted life-years). Methods: Little Australia-wide epidemiological information is available, so international studies in the main were used to estimate the incidence and prevalence by age and gender. These were triangulated against the available Australian data. Australian health data sets and data collected from the emergency department of a tertiary pediatric hospital were used to estimate the costs of primary care, pharmaceuticals, pathology and imaging, emergency department presentations, specialists, and admitted hospital care. Results: Excluding the costs of the complications and comorbidities associated with OM, treatment costs for the disease in 2008 were between AUS$100 and 400 million. Visits to general practitioners and medicines constituted a high proportion of these costs. Antibiotic prescribing rates remain high despite clear evidence for a limited benefit from antibiotics for most OM cases and concerns regarding bacterial resistance. Conclusion: Treatment costs of OM in Australia are high and can only be estimated within a broad range. Further research on the links between antibiotics for OM and antibiotic resistance, and on the cost–effectiveness of prevention or amelioration of OM would be useful.

    AB - Objective: Otitis media (OM) is an inflammation of the middle ear. It is very common and associated with serious complications, including hearing loss. This study aimed to estimate the treatment costs of OM in Australia and the associated burden of disease (in disability-adjusted life-years). Methods: Little Australia-wide epidemiological information is available, so international studies in the main were used to estimate the incidence and prevalence by age and gender. These were triangulated against the available Australian data. Australian health data sets and data collected from the emergency department of a tertiary pediatric hospital were used to estimate the costs of primary care, pharmaceuticals, pathology and imaging, emergency department presentations, specialists, and admitted hospital care. Results: Excluding the costs of the complications and comorbidities associated with OM, treatment costs for the disease in 2008 were between AUS$100 and 400 million. Visits to general practitioners and medicines constituted a high proportion of these costs. Antibiotic prescribing rates remain high despite clear evidence for a limited benefit from antibiotics for most OM cases and concerns regarding bacterial resistance. Conclusion: Treatment costs of OM in Australia are high and can only be estimated within a broad range. Further research on the links between antibiotics for OM and antibiotic resistance, and on the cost–effectiveness of prevention or amelioration of OM would be useful.

    U2 - 10.1586/erp.09.6

    DO - 10.1586/erp.09.6

    M3 - Article

    VL - 9

    SP - 133

    EP - 141

    JO - Expert review of pharmacoeconomics and outcomes research

    JF - Expert review of pharmacoeconomics and outcomes research

    SN - 1473-7167

    IS - 2

    ER -

    Taylor PS, Faeth I, Marks MK, Del Mar CB, Skull SA, Pezzullo ML et al. Cost of treating otitis media in Australia. Expert review of pharmacoeconomics and outcomes research. 2009;9(2):133-141. https://doi.org/10.1586/erp.09.6